NIH R01 and R21 for Companies: When a Research Grant Beats SBIR

A company does not have to be SBIR-eligible to hold NIH money. The NIH parent research project grants, the R01 and the R21, list "Small Businesses" and "For-Profit Organizations (Other than Small Businesses)" among eligible applicants, with no ownership rule, no citizenship rule and no 500-employee cap. They fund a scientific question, not a product launch, and that is exactly the case where they beat SBIR.

Who this fits and who it does not

The current parent announcements are PA-25-301 (R01, Clinical Trial Not Allowed, expires January 08, 2028), PA-25-305 (R01, Clinical Trial Required), PA-25-304 (R21, Clinical Trial Not Allowed) and PA-25-306 (R21, Clinical Trial Required). Their eligibility sections list higher education institutions, nonprofits, for-profit organizations including small businesses and for-profits other than small businesses, governments, and non-domestic (non-US) entities. Nothing in them restricts ownership or citizenship.

• It fits a US company whose founder or main investor is not a US citizen or permanent resident, so SBIR's ownership test fails.
• It fits a company above 500 employees once affiliates are counted, or a subsidiary of a larger group.
• It fits a company whose scientific lead is a faculty member who will not become an employee: on an R01 or R21 the PI can be whoever the applicant organization names, and multiple PIs are allowed.
• It fits a project framed as a hypothesis with aims (R01) or an exploratory idea with little preliminary data (R21), in the mission of a specific NIH institute.
• It does not fit a request to finish a product, run a launch or buy equipment. Reviewers score significance, approach, innovation, investigators and environment, and the application has to read as research.

How the process works

Applications are submitted through Grants.gov and tracked in eRA Commons; the organization needs SAM.gov, eRA Commons and Grants.gov registrations, and a foreign organization also needs an NCAGE code. Standard due dates are the NIH-wide ones: R01 new applications February 5, June 5 and October 5; R21 new applications February 16, June 16 and October 16; renewals and resubmissions one month later. The next new-application dates: February 5, 2027 (R01 new) and February 16, 2027 (R21 new); standard due dates February 5, June 5, October 5 (R01) and February 16, June 16, October 16 (R21).

Budgets differ sharply: R01: budget not limited, up to 5 years. R21: direct costs up to $275,000 over 2 years, no more than $200,000 in any year. Under PA-25-301 application budgets must reflect the actual needs of the project; under PA-25-304 the direct cost cap and the two-year limit are written in the announcement.

Counting backward from a due date for an R21: institute and study section chosen first, Specific Aims drafted next, letters from collaborators and the biosketches collected, and submission early enough for the Grants.gov and eRA checks to be corrected before the deadline.

My read

• Only a rule written in the announcement excludes an applicant. A PI without an NIH track record, thin preliminary data or a first-time organization is a risk, not an exclusion, and each risk has a fix: an academic co-PI or multiple-PI structure, an R21 before the R01, a university collaborator who brings the environment score.
• The R21 is the natural entry for a company. Two years, a capped direct-cost budget, little preliminary data expected. It is where a medical food, a diagnostic concept or a behavioral intervention can be tested as a question.
• Reviewers will ask why a company and not a university is asking the question. The honest answer, that the company owns the material, the data or the device and the question cannot be answered without it, is a good one.
• Indirect cost rates for a company are negotiated or claimed under NIH policy; I budget them in from the start so the direct cost cap is not a surprise.

Frequently asked questions

Can a company with a foreign owner apply for an R01?

Yes. PA-25-301 lists for-profit organizations and even non-domestic entities as eligible, and it contains no ownership or citizenship requirement. The SBIR ownership rule belongs to SBIR and STTR only.

Does the PI have to be employed by the company?

The announcement requires the PD/PI to have the skills, knowledge and resources to carry out the research and to be named by the applicant organization. There is no primary-employment rule like SBIR's. A multiple-PI application can pair a company scientist with an academic.

Can the grant fund product development?

Only the research part. The aims have to answer a scientific question that advances the institute's mission. Development and commercialization are what SBIR and STTR are for, and the two routes can run in sequence.

Which is better for a first application, R21 or R01?

For a company with a pilot study and no NIH history, the R21 is usually the right first application: it is designed for exploratory work with limited preliminary data and a two-year budget. An R01 expects a mature hypothesis and supporting data.